Search

IDD-1

As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen. … Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject.

XL765

XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

CoviGlobulin

The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones. … Different antibodies have different mechanisms of action depending on their target.

Evans blue

Paraoxon

Goflikicept

Goflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe

ALTU-135

This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals.

IDD-3

IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines.

Ubenimex

It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.

Lancovutide

Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis.